

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



**Simcere Pharmaceutical Group Limited**

**先聲藥業集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock code: 2096)**

## **VOLUNTARY ANNOUNCEMENT ON COOPERATION WITH LYNK PHARMACEUTICALS TO INTRODUCE SELECTIVE JAK1 INHIBITOR**

This announcement is made by Simcere Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform shareholders and potential investors of the Company about the latest business development of the Group.

The board (the “**Board**”) of directors (“**Directors**”, and each a “**Director**”) of the Company is pleased to announce that, the Group entered into a cooperation agreement with Lynk Pharmaceuticals Co., Ltd. (凌科藥業(杭州)有限公司) (“**Lynk Pharmaceuticals**”) on March 18, 2022, pursuant to which, the Group will obtain the exclusive commercialization interest of LNK01001 for rheumatoid arthritis and ankylosing spondylitis indications in China and be responsible for promotion after regulatory approval, and Lynk Pharmaceuticals will be responsible for the clinical development of LNK01001.

LNK01001 is an oral JAK1 selective inhibitor, which is expected to treat a variety of auto-immune diseases. At present, there have been three indications including rheumatoid arthritis and ankylosing spondylitis in phase 2 clinical studies. According to the existing preclinical and clinical data, LNK01001 has a higher selectivity and potentially better safety compared with JAK inhibitors already on the market, which is expected to provide patients with safer and more effective treatment options.

### **ABOUT LYNK PHARMACEUTICALS**

Lynk Pharmaceuticals is a biopharmaceutical company in the clinical stage. Focusing on the fields of cancer, immunity, inflammation and other diseases, Lynk Pharmaceuticals develops global and domestic leading new drug projects through its own research and development as well as cooperative development with both larger domestic and overseas pharmaceutical enterprises.

## **ABOUT THE COMPANY**

The Company is a company engaged in the R&D, production and commercialization of pharmaceuticals with the national key laboratory of translational medicine and innovative pharmaceuticals. The Company has a diversified product portfolio in strategically focused therapeutic areas, including (i) oncology, (ii) central nervous system diseases and (iii) autoimmune diseases, with leading positions in their respective therapeutic segments and/or established track record. The Company continues to source innovative therapies globally and established strategic partnership with several multinational companies.

By order of the Board  
**Simcere Pharmaceutical Group Limited**  
**Mr. Ren Jinsheng**  
*Chairman and Chief Executive Officer*

Hong Kong, March 18, 2022

*As at the date of this announcement, the Board comprises Mr. REN Jinsheng as the Chairman and executive Director, Mr. WAN Yushan and Mr. TANG Renhong as the executive Directors; Mr. ZHAO John Huan as the non-executive Director; and Mr. SONG Ruilin, Mr. WANG Jianguo and Mr. WANG Xinhua as the independent non-executive Directors.*